Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Trading 03-17 09:39:10 EDT

763.82

+6.91

+0.91%

High765.40	Low762.71	Vol14.52K
Open763.53	D1 Closing756.91	Amplitude0.35%
Mkt Cap80.75B	Tradable Cap78.90B	Total Shares105.72M
T/O11.09M	T/O Rate0.01%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":763.82,"timestamp":1773754750581,"preClose":756.91,"halted":0,"volume":14516,"delay":0,"changeRate":0.009129222760962442,"floatShares":103302739,"shares":105719806,"eps":41.59414,"marketStatus":"Trading","change":6.91,"latestTime":"03-17 09:39:10 EDT","open":763.53,"high":765.395,"low":762.71,"amount":11091907.42052,"amplitude":0.003547,"askPrice":764.58,"askSize":25,"bidPrice":762.85,"bidSize":2,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773777600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":756.91,"dividendRate":0.004757,"preHourTrading":{"tag":"盘前","latestPrice":761.87,"preClose":756.91,"latestTime":"09:29 EDT","volume":51,"amount":38647.244099999996,"timestamp":1773754199951,"change":4.96,"changeRate":0.006553,"amplitude":0.024005},"postHourTrading":{"tag":"盘后","latestPrice":756.91,"preClose":756.91,"latestTime":"19:46 EDT","volume":23674,"amount":17919142.96,"timestamp":1773704770709,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.207806,"impliedVol":0.3852,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2620849107","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2620849107","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620849107?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:42","pubTimestamp":1773693720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  advanced 1.49% to $756.91 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.01% to 6,699.38 and the Dow Jones Industrial Average  rising 0.83% to 46,946.41.The stock's rise snapped a two-day losing streak.Regeneron Pharmaceuticals Inc. closed 7.82% below its 52-week high of $821.11, which the company reached on January 9th.The stock outperformed some of its competitors Monday, as Amgen Inc.  rose 0.01% to $366.25, Moderna Inc.  rose 1.43% to $53.31, and Gilead Sciences Inc.  rose 0.15% to $145.21.Trading volume  remained 385,301 below its 50-day average volume of 780,839.Data source: Dow Jones Market Data, FactSet. Data compiled March 16, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswir","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2618922132","title":"FDA Approves Eylea Hd for Rare Pediatric Disease, Redeeming Priority Review Voucher - Federal Register Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:47","pubTimestamp":1773319643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","LU0823416689.USD","LU0882574055.USD","LU2362541513.USD","LU2089984988.USD","LU0114720955.EUR","LU2468319806.SGD","LU0109394709.USD","LU1974910355.USD","LU0823434740.USD","BK4588","LU2106854487.HKD","LU0320765992.SGD","REGN","LU0058720904.USD","BK4585","LU2237438978.USD","LU0053666078.USD","LU0823434583.USD","LU1917777945.USD","BK4139","LU2362540622.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2618329121","title":"FDA: Determined Supplemental Application for Eylea Hd, Approved Nov 19, 2025, Meets Criteria for Redeeming Priority Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2618329121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618329121?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:47","pubTimestamp":1773319643,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000OK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU2237438978.USD","REGN","LU2089984988.USD","LU2362541513.USD","LU0823434583.USD","LU2362540622.SGD","BK4139","LU0823416689.USD","BK4585","LU0058720904.USD","LU2106854487.HKD","LU2362541273.HKD","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU2468319806.SGD","LU0114720955.EUR","LU2023250504.SGD","LU0320765992.SGD","LU0053666078.USD","LU1917777945.USD","LU0889565916.HKD","LU0289739699.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2618797413","title":"Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271313,"startTime":"0","endTime":"0","summary":"Mesoblast appointed Teresa Montagut as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Eric Rose. Montagut will lead the medical affairs organization and support investigator-initiated trials and clinical collaborations. She joined Mesoblast from Regeneron, where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Mesoblast said Montagut will support efforts to expand indications for its cell therapy programs in pediatric and adult inflammatory conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbkSytc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0289739699.SGD","LU2210149790.SGD","LU0882574055.USD","LU2362540622.SGD","BK7501","LU0058720904.USD","LU0114720955.EUR","REGN","LU0053666078.USD","IE00BGHQF748.EUR","LU2362541513.USD","LU2095319765.USD","BK7067","LU0109394709.USD","BK7508","LU0320765992.SGD","LU2468319806.SGD","IE00B64PRP62.GBP","LU0889565916.HKD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4588","LU0823416689.USD","LU1917777945.USD","MSB.AU","LU0823434583.USD","NDAQ","BK4112","SG9999014013.SGD","LU0823434740.USD","LU2089984988.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","LU2106854487.HKD","SG9999014005.SGD","LU2023250504.SGD","LU2237438978.USD","BK4585","LU2362541273.HKD","SG9999014021.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2618928105","title":"Jefferies Remains a Buy on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928105","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928105?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:30","pubTimestamp":1773235800,"startTime":"0","endTime":"0","summary":"Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron today and set a price target of $890.00. Tewari covers the Healthcare sector, f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541273.HKD","XBI","LU0320765992.SGD","LU0823434740.USD","BK4139","LU2089984988.USD","XLV","LU0109394709.USD","LABU","BK4581","LU0823416689.USD","LU2237438978.USD","LU2362541513.USD","LU0289739699.SGD","BK4588","BK4585","LU2023250504.SGD","REGN","LU0889565916.HKD","LU2106854487.HKD","LU1974910355.USD","LU2468319806.SGD","LU0058720904.USD","LU0823434583.USD","LU0053666078.USD","LU0882574055.USD","LU0114720955.EUR","LU1917777945.USD","LU2362540622.SGD"],"gpt_icon":0},{"id":"2618949667","title":"Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2618949667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618949667?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:02","pubTimestamp":1773226920,"startTime":"0","endTime":"0","summary":"1102 GMT - Sanofi and Regeneron might face competition in the market for eczema treatments after Pfizer reported data for an experimental medicine that showed potential to be the first meaningful rival to their Dupixent blockbuster drug, Citi analysts say in a research note. In a midstage trial, Pfizer's tilrekimig achieve efficacy for eczema--also known as atopic dermatitis--with potential to be competitive against Dupixent and placebo-like safety, Citi says. Results from a late-stage study could come between 2027 and 2028 and approval a year later, suggesting tilrekimig could hurt Dupixent sales in the final years before its patents expire, the analysts say. Sanofi shares fall 0.3%. Regeneron and Pfizer are down 1.2% and 0.3%, respectively, in U.S. premarket trading. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","BK4007","LU0053666078.USD","LU1066051498.USD","IE00BLSP4452.SGD","LU0114720955.EUR","PFE","REGN","SG9999001176.SGD","BK4534","LU0823416689.USD","LU1883839398.USD","SG9999001176.USD","IE00B19Z3581.USD","LU0306806265.USD","LU0985481810.HKD","BK4568","LU0058720904.USD","LU0122379950.USD","LU2362540622.SGD","LU0225284248.USD","LU0109394709.USD","BK4585","SGXZ57979304.SGD","SG9999013999.USD","LU0823434583.USD","LU0868494617.USD","SG9999002224.SGD","IE0002270589.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","BK4592","LU0320765992.SGD","IE00BBT3K403.USD","LU2468319806.SGD","IE00BFXG1179.USD","LU2089984988.USD","LU1894683264.USD","LU1066053197.SGD","LU2362541513.USD","LU1023059063.AUD","SNY","BK4599","LU0234572021.USD","LU0306807586.USD","LU0823434740.USD","SG9999003800.SGD","LU2106854487.HKD","LU0456855351.SGD","LU0170899867.USD","LU2237438978.USD","SG9999002232.USD","LU1917777945.USD","LU2362541273.HKD","BK4581","IE00BLSP4239.USD","LU0321505439.SGD","SG9999011175.SGD","LU1057294990.SGD","BK4588","LU0889565916.HKD","LU0225771236.USD","BK4550","LU1974910355.USD","LU1894683348.USD","LU0882574055.USD","BK4139","BK4533"],"gpt_icon":0},{"id":"2618694689","title":"Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $890 From $885, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618694689","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618694689?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:36","pubTimestamp":1773225412,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2618916466","title":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2618916466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618916466?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:10","pubTimestamp":1773213002,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, OracleMarch 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"73f0b19cff544fe0a24216c0d940c1eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBG","MET","GEHC","CHH","FICO","CNC","BLND","AVAV","DBI","HIMZ","BSX","UEC","ABM","APYX","ORCU","AVR","HMYY","BMRN","ORCX","ALMS","EPRT","H","CNCG","HIMS","SJM","RNA","ORCL","BKNG","CDW","HIMY","EXPE","NKE","ORCS","ABT","CLYM","ELV","HLT","T","AVXX","HOG","DXCM","HAE","HWM","BKNU","HIYY","HAS","PGNY","REGN","CASY","ADC"],"gpt_icon":1},{"id":"2618968139","title":"Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618968139?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:29","pubTimestamp":1773192540,"startTime":"0","endTime":"0","summary":"$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competitionTARRYTOWN, N.Y. and WASHINGTON, March  10, 2026  (GLOBE NEWSWIRE) -- Regeneron Ph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3253459/0/en/Regeneron-Science-Talent-Search-2026-Recognizes-America-s-Top-Young-Scientists-Awarding-More-Than-1-8-Million-to-High-School-Seniors-for-Innovative-Research-in-Computational-Mathem.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0058720904.USD","JIA","LU0109394709.USD","LU0823434740.USD","LU0882574055.USD","LU2362541273.HKD","LU0114720955.EUR","LU0053666078.USD","LU1917777945.USD","LU1974910355.USD","LU0289739699.SGD","LU2468319806.SGD","LU0320765992.SGD","REGN","LU2362540622.SGD","BK4585","LU2237438978.USD","LU2023250504.SGD","LU2089984988.USD","LU0823434583.USD","BK4588","LU2362541513.USD","LU0823416689.USD","LU2106854487.HKD","BK4139"],"gpt_icon":0},{"id":"2618934677","title":"Scotiabank Sticks to Their Hold Rating for Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934677?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:57","pubTimestamp":1773140279,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-hold-rating-for-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-hold-rating-for-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2618672114","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672114","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672114?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:42","pubTimestamp":1773088920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rallied 2.86% to $781.60 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.83% to 6,795.99 and the Dow Jones Industrial Average  rising 0.50% to 47,740.80.The stock's rise snapped a two-day losing streak.Regeneron Pharmaceuticals Inc. closed 4.81% short of its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  rose 2.01% to $376.97, Moderna Inc.  rose 6.13% to $55.74, and Gilead Sciences Inc.  rose 1.88% to $146.63.Trading volume  remained 78,147 below its 50-day average volume of 774,922.Data source: Dow Jones Market Data, FactSet. Data compiled March 9, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2618671508","title":"BUZZ-Regeneron rises after announcing positive trial data on weight-loss drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671508","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671508?lang=en_us&edition=fundamental","pubTime":"2026-03-10 03:40","pubTimestamp":1773085215,"startTime":"0","endTime":"0","summary":"BUZZ-Regeneron rises after announcing positive trial data on weight-loss drug** Shares of Regeneron REGN.O rises ~2% to $774.29 after the company announced positive trial results of a potential weight","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX1F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK1191","LU0889565916.HKD","LU0882574055.USD","LU2362541273.HKD","LU1974910355.USD","LU2468319806.SGD","03692","BK1589","BK4588","REGN","BK1583","LU2362541513.USD","LU2362540622.SGD","LU0289739699.SGD","LU2089984988.USD","LU0823434583.USD","LU2023250504.SGD","LU0053666078.USD","LU2106854487.HKD","LU0114720955.EUR","LU0823416689.USD","LU2237438978.USD","BK4585","LU0823434740.USD","LU0058720904.USD","LU1917777945.USD","BK4139"],"gpt_icon":0},{"id":"2618946640","title":"Regeneron Pharmaceuticals Inc: Patients Treated With Olatorepatide Achieved up to 19% Body-Weight Loss at Week 48","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2XWPGZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362540622.SGD","LU0823416689.USD","LU0114720955.EUR","LU0053666078.USD","REGN","LU2362541273.HKD","LU0882574055.USD","LU1917777945.USD","LU2237438978.USD","LU1974910355.USD","BK4585","LU0109394709.USD","LU0289739699.SGD","LU2362541513.USD","LU0823434740.USD","LU2023250504.SGD","LU0320765992.SGD","LU0058720904.USD","BK4588","LU2089984988.USD","LU2106854487.HKD","LU2468319806.SGD","LU0889565916.HKD","BK4139","LU0823434583.USD"],"gpt_icon":0},{"id":"2618640976","title":"Regeneron Pharmaceuticals Inc - Olatorepatide Achieves up to 19% Mean Body-Weight Loss at Week 48","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640976?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2XWPGZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237438978.USD","LU0823434583.USD","LU2362541513.USD","LU1917777945.USD","LU0058720904.USD","LU0823416689.USD","LU2468319806.SGD","LU0823434740.USD","LU0889565916.HKD","BK4585","BK4139","LU2106854487.HKD","LU2023250504.SGD","BK4588","LU2089984988.USD","LU0882574055.USD","LU0109394709.USD","LU2362541273.HKD","LU0114720955.EUR","LU2362540622.SGD","LU0289739699.SGD","LU0053666078.USD","REGN","LU0320765992.SGD","LU1974910355.USD"],"gpt_icon":0},{"id":"2618640961","title":"Regeneron Pharmaceuticals Inc - Olatorepatide Shows Favorable Gastrointestinal Tolerability With Lower Adverse Event Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640961?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2XWPGZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","REGN","BK4588","LU1974910355.USD","LU0114720955.EUR","LU2362541273.HKD","LU0889565916.HKD","BK4139","LU0882574055.USD","LU2089984988.USD","LU0109394709.USD","LU1917777945.USD","LU0823416689.USD","LU2023250504.SGD","LU0289739699.SGD","LU2362540622.SGD","LU0823434583.USD","LU2237438978.USD","BK4585","LU2106854487.HKD","LU0058720904.USD","LU0823434740.USD","LU2362541513.USD","LU0053666078.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2618640600","title":"Regeneron Pharmaceuticals Inc - to Initiate Global Phase 3 Registration Program for Olatorepatide Later This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640600?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2XWPGZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053666078.USD","LU2362541273.HKD","LU0058720904.USD","LU1917777945.USD","LU0320765992.SGD","LU0889565916.HKD","LU2106854487.HKD","LU2237438978.USD","LU0823434740.USD","LU1974910355.USD","LU2023250504.SGD","BK4585","LU0823434583.USD","LU2089984988.USD","LU2362540622.SGD","LU0823416689.USD","LU0114720955.EUR","REGN","LU2362541513.USD","LU2468319806.SGD","BK4139","LU0109394709.USD","LU0882574055.USD","BK4588","LU0289739699.SGD"],"gpt_icon":0},{"id":"2618964026","title":"Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2618964026","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618964026?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March  09, 2026  (","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251688/0/en/Olatorepatide-Obesity-Treatment-Licensed-by-Regeneron-Demonstrates-Positive-Phase-3-Results-in-Chinese-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4588","LU0058720904.USD","LU1974910355.USD","LU2023250504.SGD","LU0114720955.EUR","LU2362541513.USD","LU0882574055.USD","LU0889565916.HKD","LU0823434740.USD","LU2362540622.SGD","BK4585","LU0109394709.USD","LU0289739699.SGD","BK4139","LU2237438978.USD","LU2362541273.HKD","REGN","LU2468319806.SGD","LU0823434583.USD","LU2106854487.HKD","LU0823416689.USD","LU0320765992.SGD","LU1917777945.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2618664014","title":"Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618664014?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:50","pubTimestamp":1773053412,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Exelixis (EXEL – Research Report), Hims & Hers Health (HIMS – Research Report) and Regeneron (REGN – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-exelixis-exel-hims-hers-health-hims-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-exelixis-exel-hims-hers-health-hims-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0823434740.USD","HIMS","BK4196","LU2362540622.SGD","EXEL","BK4585","LU0053666078.USD","HIYY","BK4532","LU0128526141.USD","LU2023250504.SGD","BK4139","LU1917777945.USD","LU0823416689.USD","LU2362541513.USD","LU0882574055.USD","LU0109394709.USD","LU2089984988.USD","HIMZ","HMYY","LU0029874061.USD","LU0289739699.SGD","LU2362541273.HKD","LU2468319806.SGD","LU1974910355.USD","REGN","HIMY","BK4581","LU0114720955.EUR","LU0058720904.USD","LU0823434583.USD","LABU","LU2237438978.USD","LU0320765992.SGD","LU2106854487.HKD","LU0889565916.HKD","XBI","BK4137"],"gpt_icon":0},{"id":"2617636473","title":"This Regeneron Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636473","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636473?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:26","pubTimestamp":1772807160,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, see analyst ratings page. What they think of REGN.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/06/Tokyo--Japan---March-10--2023-A-Shake-Sh.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/06/Tokyo--Japan---March-10--2023-A-Shake-Sh.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51095772/this-regeneron-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51095772/this-regeneron-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4588","LU0053666078.USD","LU0058720904.USD","LU1974910355.USD","LU2023250504.SGD","LU0114720955.EUR","LU2362541513.USD","LU0882574055.USD","LU0889565916.HKD","LU0823434740.USD","BLSG","BLSX","LU2362540622.SGD","BK4585","LU0109394709.USD","LU0289739699.SGD","BK4139","LU2237438978.USD","LU2362541273.HKD","REGN","LU2468319806.SGD","LU0823434583.USD","BK4112","LU2106854487.HKD","LU0823416689.USD","LU0320765992.SGD","LU1917777945.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2617163363","title":"Regeneron Pharma Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2617163363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617163363?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:57","pubTimestamp":1772805420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 08:57 ET (13:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU1917777945.USD","LU2089984988.USD","LU0058720904.USD","LU0114720955.EUR","LU2023250504.SGD","BK4588","BK4139","LU2362541273.HKD","LU2362541513.USD","LU0823434583.USD","LU2237438978.USD","LU0053666078.USD","LU2106854487.HKD","LU0823434740.USD","REGN","LU0320765992.SGD","LU0109394709.USD","BK4585","LU2362540622.SGD","LU0889565916.HKD","LU0823416689.USD","LU0289739699.SGD","LU1974910355.USD","LU0882574055.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":-0.0576},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.2928},{"period":"1year","weight":0.135},{"period":"ytd","weight":-0.0194}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043957},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction